• Direct.Last minute on the news of coronavirus in Spain

  • Salud.AstraZeneca suspends trials of Oxford vaccine due to "serious adverse reaction" of a volunteer

  • Reactions: The nine pharmaceutical giants sign a pact not to give in to political pressure to manufacture a vaccine

  • Sequelae - What is transverse myelitis, the AstraZeneca vaccine volunteer disease?

The vaccine race has a bump, as often happens in the search for a new molecule in science: learning based on trial and error.

The American multinational AstraZeneca has voluntarily and temporarily interrupted the trials with its AZD1222 vaccine against Covid-19 because one of the participants in the branch of the study being carried out in the United Kingdom has experienced "a potentially disease inexplicable, "according to company sources.

"As part of the ongoing global randomized controlled clinical trials for the development of the Oxford coronavirus vaccine,

our standard review process has been activated

and it has been decided to voluntarily discontinue vaccination to allow review of safety data by an independent committee.This is a

routine action

that is taken, while investigating what happened, whenever a potentially unexplained disease is observed in one of the trials to ensure that the integrity of the themselves ".

From AstraZeneca they add that "in large trials, diseases

can appear by chance

and must undergo a thorough study by an independent body. We are working to

speed up the review of this single case

in order to minimize any potential impact on the timing of the clinical study. We are committed to the safety of the participants and maintaining the highest standards in conducting our clinical trials. "

AstraZeneca had started phase III of its trial in the United States at the end of August, while in the United Kingdom, Brazil and South Africa, the vaccine study was between phases II and III.

AstraZeneca sources have told this newspaper that the company

was considering launching trials also in Japan and Russia

.

Among all the studies, the aim is to

measure immune responses in different age groups and at different doses

.

"All these trials, together with the phase III clinical trial in the United States, would include up to

50,000 participants worldwide,

" say the same sources, who expected "the results of the

last-stage

trials by the

end of this year

, depending infection rate within clinical trial communities, "although now the timelines will depend on the incident review.

AstraZeneca expected to have its vaccine available by the first half of 2021 and was considered one of the most advanced in the world by the World Health Organization (WHO).

Promising data

In the company's research to date, data from the ongoing phase I / II COV001 trial published in July in

The Lancet stand out

.

These data "are encouraging, since they show that AZD1222 achieved potent immune responses in all participants and generated a rapid induction in both antibodies and T lymphocytes against the virus. The most relevant results of this trial reveal that a single dose of AZD1222 multiplied by four antibodies against the SARS-CoV-2 virus protein S in 95% of the participants one month after injection. In addition, a T-lymphocyte response was induced in all participants, which reached its maximum on day 14 , and it was maintained two months after the injection. "

"It should be noted - the same sources add to this newspaper - that neutralizing activity against SARS-CoV-2 (MNA80) was observed in 91% of the participants one month after vaccination and in one hundred percent of the participants after of a second dose.

Neutralizing antibody levels were similar to those seen in convalescent Covid-19 patients

after a second dose. "

Among other agreements for the eventual distribution of the vaccine,

AstraZeneca has reached one with the European Commission for the distribution of up to 400 million doses

, with deliveries that were scheduled for before the end of 2020, and among which the Spanish Government had announced the forecast of having in that month the three million doses that would initially correspond to Spain.

According to the criteria of The Trust Project

Know more

  • Science and Health

  • Covid 19

  • Vaccinations

  • Coronavirus

  • Health

  • Pharmacology

Health "Not all countries can carry out phase II trials of a vaccine"

Covid-19 Why would the Covid vaccine be in Spain in December?

Moderna's vaccine offers high protection against covid in people over 60 years of age

See links of interest

  • News

  • Coronavirus

  • Translator

  • Programming

  • Horoscope

  • Classification

  • Films

  • Topics

  • 11th stage of the Tour de France, live: Chatelaillon-Plage - Poitiers